No Data
Mengke Pharmaceutical: Shanghai Mengke Pharmaceutical Co., Ltd. Report for the first quarter of 2025
Shanghai Menko Pharmaceutical Co., Ltd. First Quarter Report of 2025.
Mengkang Pharmaceutical (688373.SH): net loss of 61.6325 million yuan in the first quarter.
Gelonghui April 23丨Mengke Pharmaceutical (688373.SH) announced the first quarter report for 2025, achieving revenue of 33.217 million yuan during the reporting period, a year-on-year increase of 0.61%; the Net income attributable to shareholders of the listed company was -61.6325 million yuan; the EPS was -0.09 yuan.
Is Shanghai MicuRx Pharmaceutical (SHSE:688373) A Risky Investment?
MicuRx: 15 Clinical and Preclinical Research Studies to Be Presented at ESCMID Global 2025
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.